Your browser doesn't support javascript.
Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.
Julian, Katherine; Bucher, Donald; Jain, Rohit.
  • Julian K; Penn State College of Medicine, Hershey, Pennsylvania, USA kjulian1@pennstatehealth.psu.edu.
  • Bucher D; Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA.
  • Jain R; Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA.
BMJ Case Rep ; 14(5)2021 May 24.
Article in English | MEDLINE | ID: covidwho-1242198
ABSTRACT
We describe the case of a 65-year-old male who presented to an outside hospital for shortness of breath, nausea and vomiting 8 days after testing positive for COVID-19. Initial workup revealed massive bilateral pulmonary emboli and thrombocytopenia. The patient was then admitted to our hospital, received an inferior vena cava filter and initially started on argatroban for autoimmune heparin-induced thrombocytopenia (HIT) prophylaxis. On hospital stay day 6, labs revealed a diagnosis of HIT in the setting of COVID-19. This case highlights the rare occurrence of a patient developing HIT without heparin exposure and in the setting of a novel infectious agent, COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombocytopenia / COVID-19 Type of study: Case report Limits: Aged / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: Bcr-2021-243315

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombocytopenia / COVID-19 Type of study: Case report Limits: Aged / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: Bcr-2021-243315